EQUATE
EQUATE asks whether adding bortezomib after initial daratumumab, lenalidomide and dexamethasone improves survival in newly diagnosed myeloma without planned early transplantation. Clinicians in the sources reviewed for this edition differ on who needs intensification and when. MRD's prognostic role and research alternatives attract interest in their commentary, while treatment toxicity draws scrutiny. Whether sequential addition improves survival, and when maintenance can stop, remain open.
- NCT04566328 ↗
- v1.0.0 · edition 1
- updated Oct 18, 2026
- Deep
13 findings, and what sits behind each
01. The central question is who needs bortezomib, and when—not whether deeper responses justify intensification for everyone
17 statements · 20 passages · 4 sources · 2 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Population and setting, Primary endpoint: Consolidation overall survival, Secondary endpoints, Design and conduct.
02. Safety concerns are regimen- and time-dependent; neither efficacy nor toxicity is treated as a class-wide quadruplet effect
26 statements · 18 passages · 2 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Secondary endpoints.
03. MRD is valued as prognostic information, but positivity is not an automatic mandate to escalate
20 statements · 17 passages · 4 sources · 0 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Consolidation overall survival, Secondary endpoints, The comparison.
04. Maintenance discontinuation attracts support, but neither the stopping time nor an MRD rule is settled
20 statements · 17 passages · 4 sources · 2 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Safety and tolerability.
05. Fitness and transplant intent require reassessment; chronological age alone is an inadequate substitute
24 statements · 16 passages · 3 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, Design and conduct.
06. Cross-trial comparisons are challenged on population, schedule and censoring—not simply biology
20 statements · 16 passages · 2 sources · 4 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison.
07. Blood-based monitoring is discussed as complementary to marrow, not a validated replacement
31 statements · 25 passages · 3 sources · 1 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
08. Routine-care adaptation prioritizes sustainable doses and less dexamethasone
9 statements · 6 passages · 3 sources · 1 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
09. Bispecific and CAR T alternatives generate interest, but the trial-versus-standard-care boundary is explicit
35 statements · 27 passages · 2 sources · 4 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
10. Risk labels and precision-treatment tools are not treated as interchangeable or settled
25 statements · 24 passages · 5 sources · 5 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting.
11. Access and representation affect what treatment choices and prediction models can deliver
17 statements · 10 passages · 2 sources · 2 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, Design and conduct.
12. Supportive care and patient preferences are part of the treatment decision, not a fallback after disease-directed therapy
28 statements · 13 passages · 2 sources · 2 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
13. Trial awareness is visible, but repeated link sharing is not endorsement or evidence of uptake
14 statements · 109 passages · 92 sources · 1 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Design and conduct, Population and setting.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 13
The central question is who needs bortezomib, and when—not whether deeper responses justify intensification for everyone
- statements
- 17
- passages
- 20
- sources
- 4
- named voices
- 2
What the statements areViews 10Questions and uncertainty 3Clinical experience 2Comparisons 0Restated results and context 2How passages are usedSupporting a statement 21Giving context 11Recorded with the finding- Counterview: recorded
- Limitations: 2
- Feeds the Medical Affairs question
- 1 post or article
- 3 podcasts and video
Draws on: The comparison, Population and setting, Primary endpoint: Consolidation overall survival, Secondary endpoints, Design and conduct.
In the full report: the interpretation in full, all 17 statements cited to source and date, and the 4 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full EQUATE report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
For which patients does adding bortezomib provide sufficiently durable disease control without unacceptable neuropathy, infection burden or loss of quality of life?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 246HCP commentary sources screened
- 101sources cited by verified HCP statements
- 12found in screened sources
- 4matched to verified clinician profiles
- 12voices cited in the report
- 352verified statements, each linked to its source
- 14of them from speakers with a confirmed clinical role
- 13findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Deep) is set by the 352 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 14 sections | Paid |
| Verified statements with short source quotes and links | 352 | Paid |
| Trial aspects mapped | 17 | Free |
| Sources with links | 101 | Counts free |
| Speaker attribution for cited voices | 12 | Paid |
Trial aspects
17 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Consolidation overall survival | 4 | 2 |
| Secondary endpoints | 6 | 1 |
| Population and setting | 11 | 3 |
| The comparison | 7 | 2 |
| Safety and tolerability | 12 | 2 |
| Design and conduct | 7 | 17 |
| MRD as information versus a trigger for intensification | 18 | 4 |
| Maintenance duration and conditions for stopping | 18 | 4 |
| Dynamic fitness, transplant alternatives and older-patient applicability | 21 | 2 |
| Comparator selection and cross-trial interpretation | 20 | 2 |
| Marrow, blood, serum and imaging in response monitoring | 32 | 3 |
| Dose, schedule and dexamethasone adaptation in routine care | 9 | 3 |
| Research alternatives for response deepening and earlier immune therapy | 35 | 2 |
| Risk definitions, prognostic work-up and precision-treatment selection | 25 | 5 |
| Treatment access, specialist referral and representative evidence | 17 | 2 |
| Supportive care, observation choices and patient decision support | 27 | 2 |
| Trial dissemination and the gap between guidelines and active practice | 14 | 92 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 234 | 92 | |
| YouTube | 12 | 9 |
max 31 / quarter
- Screened window
- Jul 27, 2022 → Oct 15, 2026
- Cited window
- Jul 27, 2022 → Oct 15, 2026
- Retrieved
- Oct 18, 2026
The trial
from ClinicalTrials.gov- Title
- Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
- Registry
- NCT04566328
- Study IDs
- EAA181 · NCI-2020-06647 (CTRP (Clinical Trial Reporting Program)) · U10CA180820
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Collaborators
- National Cancer Institute (NCI)
- Design
- Phase 3 · Interventional, randomized, sequential
- Status
- Recruiting
- Enrollment
- 1,450 estimated
- Start
- 2021-02-24 actual
- Primary completion
- 2027-12-31 estimated
- Primary endpoint
- Consolidation overall survival
- Interventions
- 5 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 105 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative sample of all HCP opinion. Repeated posts from one author do not establish consensus or prescribing uptake.
- Many recording passages cannot be assigned confidently to a named individual. Their views are reported anonymously rather than inferred from a program, participant list or professional profile.
- No exact-trial publication or standalone protocol was available. Study descriptions in commentary must therefore remain speakers' accounts, and other-trial results must not be read as EQUATE outcomes.
- Some social-media conversations and one podcast were unavailable. Other passages in included recordings were not fully assessed, including parts of the discussion of early MRD-guided transplant omission, slow response and sustained negativity.
- The reported direction of BENEFIT's MRD comparison differs between a speaker's post and the later podcast account. Both are preserved as source-specific statements rather than reconciled into a single result.
- Several numerical comparisons are approximate recollections or cross-trial observations. Censoring explanations, exposure interpretations and proposed reasons for age limits are hypotheses, not demonstrated analyses in this edition.
- Future stopping strategies, blood-monitoring algorithms, genetic prediction tools and earlier immune-therapy sequences remain conditional or investigational in the statements cited.
- The supplied registry description of the treatment comparison is abbreviated. The report does not reconstruct missing regimen details or infer current recruitment from an announcement's activation date.
How reports are built and checked: Methods.
Editions and corrections
freeShow all 4 corrections
None of these corrections changed a finding.
- Oct 19, 2026Report description rewritten to say where clinicians' views stand, not only what they discuss
- Oct 19, 2026taxonomy mapping corrected
- Oct 27, 2026Corrected to match the delivered report: the open question for Medical Affairs; per-finding counts; source breakdowns; the limitations; source quotations and links in the paid report. Other trials' names are spelled as their investigators write them, outside quotations: “MajesTEC” (was “Majestic”).
- Oct 28, 2026The trial is named EQUATE, as its sources and the report name it (was EAA181)
Last checked for new commentary Oct 18, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.
Cite this report
Erudio Health. EQUATE (NCT04566328): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 18, 2026. https://www.erudio.com/reports/equate-nct04566328
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "EQUATE" (NCT04566328), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "equate-04566328". If you cannot make requests, read https://www.erudio.com/reports/equate-nct04566328.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04566328", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04566328 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/equate-nct04566328.json
curl https://www.erudio.com/reports/equate-nct04566328.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "equate-04566328" })release 62abfcbc36931a184523631fd32363c5318b0f415c2eec9a4587194362c57fba